TriangleNCT01775475 · OUTCOME
Change in Absolute CD4 Count From Baseline to Post-treatment
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEAN
- Unit
- cells per mm^3
- Interval / dispersion
- Standard Deviation
- Time frame
- From baseline to 18 weeks
What was measured
Change in absolute CD4 count from baseline to post-treatment (visit 6)
Analysis population: Participants who had absolute CD4 count measurements at baseline and visit 6
Groups in this outcome
Arm I (CHOP)
Patients receive CHOP chemotherapy comprising cyclophosphamide IV on day 1, doxorubicin hydrochloride IV on day 1, vincristine sulfate IV on day 1, and prednisone PO on days 1-5. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. cyclophosphamide: Given IV doxorubicin hydrochloride: Given IV vincristine sulfate: Given IV prednisone: Given PO laboratory biomarker analysis: Correlative studies
Arm II (Oral Chemotherapy)
Patients receive lomustine PO QD on day 1 (courses 1 and 3 only), etoposide PO QD on days 1-3, cyclophosphamide PO QD on days 22-26, and procarbazine hydrochloride PO QD on days 22-26. Treatment repeats every 6 weeks for up to 3 courses in the absence of disease progression or unacceptable toxicity. lomustine: Given PO etoposide: Given PO cyclophosphamide: Given PO procarbazine hydrochloride: Given PO laboratory biomarker analysis: Correlative studies
| Group | Source count |
|---|---|
| Arm I (CHOP) | 3 |
| Arm II (Oral Chemotherapy) | 3 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Arm I (CHOP) | -41.3 | 136.5 | Not reported | Not reported | Not reported |
| Arm II (Oral Chemotherapy) | 203.3 | 153.1 | Not reported | Not reported | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- spread
- 136.5
- value
- -41.3
- group Id
- OG001
- spread
- 153.1
- value
- 203.3
- denoms
- counts
- group Id
- OG000
- value
- 3
- group Id
- OG001
- value
- 3
- units
- Participants
- description
- Change in absolute CD4 count from baseline to post-treatment (visit 6)
- dispersion Type
- Standard Deviation
- groups
- description
- Patients receive CHOP chemotherapy comprising cyclophosphamide IV on day 1, doxorubicin hydrochloride IV on day 1, vincristine sulfate IV on day 1, and prednisone PO on days 1-5. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. cyclophosphamide: Given IV doxorubicin hydrochloride: Given IV vincristine sulfate: Given IV prednisone: Given PO laboratory biomarker analysis: Correlative studies
- id
- OG000
- title
- Arm I (CHOP)
- description
- Patients receive lomustine PO QD on day 1 (courses 1 and 3 only), etoposide PO QD on days 1-3, cyclophosphamide PO QD on days 22-26, and procarbazine hydrochloride PO QD on days 22-26. Treatment repeats every 6 weeks for up to 3 courses in the absence of disease progression or unacceptable toxicity. lomustine: Given PO etoposide: Given PO cyclophosphamide: Given PO procarbazine hydrochloride: Given PO laboratory biomarker analysis: Correlative studies
- id
- OG001
- title
- Arm II (Oral Chemotherapy)
- param Type
- MEAN
- population Description
- Participants who had absolute CD4 count measurements at baseline and visit 6
- reporting Status
- POSTED
- time Frame
- From baseline to 18 weeks
- title
- Change in Absolute CD4 Count From Baseline to Post-treatment
- type
- PRIMARY
- unit Of Measure
- cells per mm^3
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice